Novartis, CH0012005267

Novartis stock trades at EUR 128.19 with minus 0.07 percent

Published on 09/30/2026 at 11:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis stock trades at EUR 128.19 on September 30, 2026, with minus 0.07 percent versus the prior close. Deutsche Bank targets CHF 120.00 after trial setbacks.

Forscherin in weißem Kittel pipettiert in Reagenzglas im sterilen Pharmalabor — Novartis AG CH0012005267 – Forscherin pipettiert präzise in steriler Pharmalaborumgebung mit Reagenzgläsern, Illustration mit AI erstellt.

Novartis stock (ISIN CH0012005267) trades at EUR 128.19 at Lang & Schwarz on September 30, 2026, with minus 0.07 percent versus the prior close of EUR 128.28. The central issue for the pharmaceutical group is pipeline confidence after two clinical setbacks and a sharp reassessment by Deutsche Bank.

Deutsche Bank cuts its target

According to Investing.com on September 9, 2026, Deutsche Bank downgraded Novartis from Buy to Hold and cut its price target from CHF 140.00 to CHF 120.00. The bank linked the decision to disappointing results for del-desiran in DM1 and the earlier pelacarsen setback.

The revised target is CHF 8.19 below the Lang & Schwarz price when comparing currencies is avoided; the analyst target is a separate Swiss franc reference, not a conversion of the euro quote. The report also cited patent-cliff pressure across Cosentyx, Kisqali and Kesimpta in the early 2030s.

Q2 figures set the earnings base

MarketBeat reported that Novartis posted quarterly revenue of USD 14.95 billion and earnings of USD 2.41 per share for the quarter reported in 2026. The same report described a Hold consensus with an average target of USD 153.00, based on six Buy ratings and ten Hold ratings.

Novartis lists its second quarter 2026 results as released on July 21, 2026, on its Novartis investor page. The figures give investors a concrete earnings base, while the analyst split shows how pipeline execution now competes with current profitability in the stock narrative.

October 26 is the next checkpoint

MarketScreener lists October 26, 2026, as the earnings release date for Novartis third quarter 2026 results. That date will put the latest operating performance against the current valuation debate.

Novartis stock holds near EUR 128

At Lang & Schwarz, Novartis stock was trading at EUR 128.19 on September 30, 2026, at 11:17 a.m. CEST, down EUR 0.09 or minus 0.07 percent versus the prior close of EUR 128.28. The market capitalization stood at USD 277.0 billion as of September 29, 2026.